Construction of paclitaxel-based antibody–drug linker conjugates with a PEGylated linker to achieve superior therapeutic index

Dear Editor,

The selection of linkers and payloads plays a crucial role in determining the therapeutic indices of antibody–drug conjugates (ADCs). Valine–citrulline (Val–Cit) coupled with a self-immolative ρ-aminobenzyl (PAB) spacer as a cleavable dipeptide linker, designated as “VC linker” in this letter, has been popularly used in ADC conjugation. However, VC linker is highly hydrophobic and, together with hydrophobic payloads at high DARs (drug-to-antibody ratios), may turn ADC molecules that have hydrophilic parts in their antibody portions, into aggregation-prone “sulfactant-like” structures. Aggregation of ADCs in vivo may lead to accelerated plasma clearance, suboptimal efficacy, and increased toxicity.

Trophoblastic cell-surface antigen-2 (Trop-2) is not only over-expressed in a variety of solid human carcinomas, but also expressed at variable levels in crucial normal tissues like skin and mucosa, making it a druggable but risky target for ADC therapies. IMMU-132, a Trop-2-targeting ADC molecule using SN38, a moderate-toxicity payload, together with a PEGylated acid-labile linker, has been approved by the FDA in April 2020 for treating triple-negative breast cancer (TNBC). However, another Trop-2-targeting ADC molecule, RN927C, which adopts more toxic auristatin-derived payload Aur0101 and a hydrophobic linker, was terminated early in Phase I clinical trial (NCT02122146) due to excess toxicity, highlighting that the key of success in targeting Trop-2 with ADC technologies is to screen for optimal linker and payload combinations in order to achieve the highest therapeutic index.

As paclitaxel (PTX) has been used therapeutically in pancreatic cancer and TNBC, in which Trop-2 is highly expressed, it appears to be a viable payload option for Trop-2-targeting ADCs. However, poor aqueous solubility of PTX has impeded its therapeutic application in carcinomas. To overcome solubility problem, more hydrophilic PTX derivatives and prodrugs, as well as ADCs, have been tested. Up to date, however, PTX-conjugated ADCs failed to exhibit sufficient anticarcinogenic effects in vivo, or did they progress to clinical development stage? The cause of unsatisfactory preclinical results has not been fully understood, but maybe in part by the simultaneous use of hydrophobic linkers with ultra-hydrophobic PTX.

In a separate study (unpublished), we have optimized PEGylation in MMAE-conjugated ADCs and found that replacing citrulline with lysine in a cleavable dipeptide “VC linker” and incorporating linear PEG24 to lysine’s free amino group as a parallel branch (peg4-Val-Lys(PEG24)-PAB, designated as “VK linker” in this letter, see [Fig. 1a]) rendered the most stability and hydrophilicity to ADC molecules. By using the VK linker, we successfully generated a stable PTX-conjugated ADC and, designated as hRS7-VK-PTX (Fig. 1a), with a high DAR value at 8 (Fig. 1b). However, our effort to conjugate PTX to hRS7 through a hydrophobic VC linker failed because this molecule precipitated completely from solution during preparation, supporting the concept that combining hydrophobic linkers with ultra-hydrophobic payloads would impair molecular stability of ADC molecules. For comparison purpose, we also conjugated payload MMAE (auristatin E) and SN38 to hRS7 with DAR value at 8, namely hRS7-VK-MMAE and hRS7-VK-SN38 (Fig. 1b; Supplementary Figs. 1 and 2a). MMAE cannot be used as a free drug therapeutically due to excessive toxicity, but has gained popularity as an ADC payload. SN38 is a moderate-toxicity payload used in IMMU-132 mentioned above. Both MMAE and SN38 are hydrophobic but not as much as PTX (data not shown).

After conjugation to hRS7 with a VK linker, none of the three ADCs showed severe aggregation and degradation even after incubation at 60 °C for 1 h (Supplementary Fig. 2c, d, e), indicating that PEGylation linker can improve the stability of ADC molecules with hydrophobic payloads.

In cancer cell lines with diverse Trop-2 expression levels, our results indicated that free drug PTX is not as potent as MMAE, but similar to SN38 (Supplementary Table 1, Supplementary Figs. 3 and 4). As ADC, rather surprisingly, hRS7-VK-PTX was more potent than hRS7-VK-MMAE and hRS7-VK-SN38 in moderate Trop-2 expression cancer cell lines, including Capan-1, NCH2452, MDA-MB-231, COLO205, and SK-MES-1 (Supplementary Table 2 and Supplementary Fig. 5). In addition, hRS7-VK-PTX even showed efficacy in PTX-resistant cancer cell lines, including SKBR3, CFPAC-1, MDA-MB-231, and COLO205 (Fig. 1h). Therefore, employment of a hydrophilic linker in PTX-conjugated ADC, as we hypothesized, significantly enhanced the anticarcinogenic potency of PTX in vitro.

The internalization rate of ADCs may impact their efficiency of cancer cell killing. Interestingly, internalization of hRS7-VK-PTX was faster than that of hRS7-VK-MMAE and hRS7-VK-SN38 (Fig. 1g). Under a confocal microscope, hRS7-VK-PTX molecules co-localized with lamp-1 and clathrin’s heavy chains, suggesting that they were internalized via clathrin-mediated endocytosis and trafficked into lysosomal compartments. In comparison, hRS7-VK-SN38 showed no obvious internalization (Fig. 1f). These results revealed that hRS7-VK-PTX can trigger a faster internalization rate, which may translate into superior therapeutic efficiency.

We then determined the therapeutic potentials of hRS7-VK-PTX in tumor xenograft models. hRS7-VK-PTX was more efficacious than hRS7-VK-SN38 in suppressing the growth of BXPC-3, COLO205, and HCC1806 cell-derived tumor xenografts (Fig. 1c; Supplementary Figs. 6 and 7). Moreover, hRS7-VK-PTX at 5 mg/kg (0.12 mg/kg PTX equivalent) was more efficacious than PTX at 10 mg/kg in suppressing the growth of BxPC-3 cell-derived xenografts (P = 0.0248, Supplementary Fig. 6a). In HCC1806 cell-derived models, the efficacy of hRS7-VK-PTX at 30 mg/kg (1.3 mg/kg PTX equivalent) was comparable with PTX at 10 mg/kg (Supplementary Fig. 6b). These results suggested that adoption
of a hydrophilic linker in PTX-conjugated ADC significantly improved its antineoplastic effect in vivo.

We also verified the “bystander killing” of hRS7-VK-PTX in tumor xenograft models, which is necessary when targets are expressed heterogeneously in tumor tissues, and is driven by transferring of released payloads from the antigen-expressing cells to the neighboring antigen-absent cells. In our study, a mixture of Trop-2-positive BXPC-3 and Trop-2-negative NCIH1688 cells, or NCIH1688 cells alone were inoculated into BALB/c-nu/nu mice (Fig. 1e, right panel). The heterogeneity of Trop-2 expression in
mixed cell-derived tumor xenografts and the negative control was confirmed by IHC (Supplementary Figs. 9b, c). Even though PTX as a free drug was much less potent than MMAE, treatment with both hRS7-VK-PTX (10 mg/kg) and hRS7-VK-MMAE (3 mg/kg) significantly suppressed co-inoculated tumor growth with comparable tumor growth inhibition (TGI) indexes at 99.5% and 91.7% (Fig. 1e; Supplementary Fig. 9a). However, hRS7-VK-MMAE, but not hRS7-VK-PTX, suppressed tumor growth in mice inoculated with NCHI1688 cells alone (Fig. 1e; Supplementary Fig. 9a), despite the absence of Trop-2 expression in tumor xenografts. These results confirmed that "bystander killing" from hRS7-VK-PTX exists and also suggested that the cell killing of hRS7-VK-PTX is more Trop-2-specific than that of hRS7-VK-MMAE, which may translate into a better safety profile clinically. Indeed, hRS7-VK-PTX (3 or 10 mg/kg) did not cause stress or body weight loss in treated mice (Supplementary Fig. 8), in sharp contrast to hRS7-VK-MMAE (3 mg/kg), hRS7-VK-SN38 (3 or 10 mg/kg), and PTX-alone treatment groups.

Last, we looked experimentally at the safety profile of hRS7-VK-PTX at relatively high doses in BALB/c mice. Although the maximum tolerable dose (MTD) of hRS7-VK-PTX was not reached due to limited reagent availability, it showed no obvious signs of toxicity or body weight loss at one single 100 mg/kg dosage when compared with placebo (Fig. 1d). In contrast, hRS7-VK-MMAE at only 60 mg/kg caused severe stress in mice as well as more than 15% of body weight loss (Supplementary Fig. 10). Therefore, hRS7-VK-PTX has a more favorable safety profile than that of hRS7-VK-MMAE.

To conclude, we have overcome the barrier of using PTX as ADC payload by introducing a hydrophilic linker. ADC molecules employing PTX, hydrophilic linkers, and Trop-2 antibodies showed superior efficacy and safety profile in vitro and in vivo, suggesting that it is a promising targeted therapeutic for human carcinomas.

ACKNOWLEDGEMENTS
This work was supported by the China National Grand S&T Special Project (2019ZX09732002-006), the Strategic Priority Research Program of the Chinese Academy of Sciences (CAS) (XDA12002023 and XDA12002030), the National Natural Science Foundation of China (81872785 and 81673347), and Shanghai Municipal Commission of Science and Technology of China (1743190400 and 19YF1457400).

AUTHOR CONTRIBUTIONS
T.S., T.C., Y.C., X.L., Y.-L.C., Q.W., T.Z., and M.-J.G. performed the experiments. T.S., T.C., Y.-L.C., T.Z., M.-J.G., and H.L. prepared experimental materials. Y.C. contributed to internalization assay. T.S. and X.L. measured Trop-2 expression in various cancer cell lines. T.S. and T.C. contributed to efficacy and toxicity assessments. C.W. and T.S. are responsible for conceptual design, data analysis, paper writing, and submission.

ADDITIONAL INFORMATION
The online version of this article (https://doi.org/10.1038/s41392-020-00247-y) contains supplementary material, which is available to authorized users.

Competing interests: Y.-L.C. and C.W. are employees of Dartsbio Pharmaceuticals Ltd. T.Z., M.G., and H.L. are employees of Levena Biopharma. The remaining authors declare no competing financial interests.

Ting Shao1, Tianzhi Chen1, Yuning Chen1, Xiaoyue Liu1, Yi-Li Chen2, Qi Wang3, Tong Zhu1, Maojun Guo3, Hui Li4, Dianwen Ju1,2 and Chunhe Wang1,2
1Biotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200126, China; 2Dartsbio Pharmaceuticals, 52840 Zhongshan, Guangdong, China; 3Levena Biopharma, 8B-301, 218 Xinghu Street, SIP, Suzhou, Jiangsu 215123, China and 4Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, 201203 Shanghai, China
Correspondence: Dianwen Ju (dianwenju@fudan.edu.cn) or Chunhe Wang (wangc@simm.ac.cn)

REFERENCES
1. Beck, A. et al. Strategies and challenges for the next generation of antibody–drug conjugates. Nat. Rev. Drug Discov. 16.5, 315–337 (2017).
2. Lyon, R. P. et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat. Biotechnol. 33, 733–735 (2015).
3. Kirsty, D. et al. Immunogenicity of therapeutic proteins: Influence of aggregation. J. Immunotoxicol. 11.2, 99–109 (2013).
4. Zaman, S., Jadid, H., Denson, A. C. & Gray, J. E. Targeting Trop-2 in solid tumors: future prospects. Onco. Targets Ther. 12, 1781–1790 (2019).
5. Velani, A. et al. CHAPTER 6: colchicine-, vinblastine-, taxol- and eribulin-based payloads for antibody–drug conjugates (ADCs). Cytotoxic Payloads for Antibody–Drug Conjugates. 118–136 (2019).